

BUY

TP: Rs 700 | ▲ 26%

AUROBINDO PHARMA

Pharmaceuticals

08 August 2019

Good beat; progress on facility issues & Sandoz are key catalysts

Q1FY20 revenue/EBITDA beat estimates by 8%/10% spurred by strong US sales at US\$ 384mn and 260bps gross margin expansion YoY and QoQ. Net debt has reduced by US\$ 131mn QoQ following a drop in working capital in the US.

Injectable sales were flat QoQ which should improve from Q3. Reinspection for three API units will take place post Dec'19 (CAPAs under implementation). We cut FY20/FY21 EPS by 2-3% to Rs 48/Rs 51, trim our EV/EBITDA multiple to 9x (vs. 10x) on FDA worries, and reset TP to Rs 700 (vs. Rs 810).

Vivek Kumar

research@bobcaps.in

Strong gross margins backed by US sales: Aurobindo Pharma (ARBP) reported strong US sales of US\$ 384mn, up 9% QoQ, led by higher volumes in OSDs and Valsartan. Spectrum contributed US\$ 25mn in Q1. Gross margins were strong, rising 260bps to 57.8% (vs. 55.5% in FY19) on higher US contribution. Injectable sales stayed flat QoQ at US\$ 67mn and management has guided for similar Q2 sales, but improvement in H2. Further, ARBP believes Eugia ramp-up and new approvals from Unit 4 should counter the generic impact in Ertapenem (another generic expected besides Apotex that launched in May'19).

Ticker/Price	ARBP IN/Rs 555
Market cap	US\$ 4.6bn
Shares o/s	586mn
3M ADV	US\$ 26.8mn
52wk high/low	Rs 838/Rs 537
Promoter/FPI/DII	52%/19%/15%

Source: NSE

FDA worries could weigh on stock: We lower our EV/EBITDA multiple to 9x from 10x earlier and EPS estimates by 2-3% for FY20/FY21 to account for potential disruption in US sales from facility resolution delays. This results in a revised TP of Rs 700 (Rs 810 earlier). We retain BUY on favourable risk-reward as the stock appears to be pricing in the worst of the facility risk and some part of Unit 3 escalation. Overall, we expect US sales (ex-Sandoz) to log an ~8% CAGR for FY19-FY21, with combined sales of US\$ 2.2bn in FY21.

STOCK PERFORMANCE



Source: NSE

Near-term downside risks: (1) adverse outcome of FDA inspection at formulation Unit 7 (10% of topline) and Unit 3, (2) Sandoz consolidation delays, (3) penalty risk from Aceto supply-chain sabotage claim (in District court).

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Adj. net profit (Rs mn)	24,227	24,126	28,087	29,815	30,290
Adj. EPS (Rs)	41.3	41.2	47.9	50.9	51.7
Adj. EPS growth (%)	5.3	(0.4)	16.4	6.2	1.6
Adj. ROAE (%)	23.1	18.8	18.5	16.8	14.8
Adj. P/E (x)	13.4	13.5	11.6	10.9	10.7
EV/EBITDA (x)	9.4	9.1	7.6	7.8	7.4

Source: Company, BOBCAPS Research

BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda

Important disclosures, including any required research certifications, are provided at the end of this report.



FIG 1 – QUARTERLY PERFORMANCE

(Rs mn)	Q1FY20	Q1FY19	YoY (%)	Q4FY19	QoQ (%)	Q1FY20E	Var (%)
Net Sales	54,446	42,502	28.1	52,921	2.9	50,379	8.1
EBITDA	11,466	7,793	47.1	10,603	8.1	10,401	10.2
Depreciation	2,408	1,545	-	1,866	-	1,763	-
EBIT	9,058	6,248	45.0	8,737	3.7	8,638	-
Interest	499	295	-	500	-	450	-
Other Income	110	437	-	323	-	325	-
PBT	8,669	6,390	35.7	8,560	1.3	8,513	1.8
Less: Taxation	2,277	1,155	-	2,311	-	2,128	-
Less: Minority Interest	0	4	-	0	-	0	-
Recurring PAT	6,392	5,231	22.2	6,249	2.3	6,384	0.1
Exceptional items	(126)	(681)	-	(384)	-	0	-
Reported PAT	6,265	4,550	37.7	5,865	6.8	6,384	(1.9)
Key Ratios (%)							
Gross Margin	57.8	55.1	-	55.2	-	55.5	-
EBITDA Margin	21.1	18.3	-	20.0	-	20.6	-
Tax / PBT	26.3	18.1	-	27.0	-	25.0	-
NPM	11.7	12.3	-	11.8	-	12.7	-
EPS (Rs)	10.9	8.9	-	10.7	-	10.9	-

Source: Company, BOBCAPS Research

FIG 2 – REVENUE MIX

(Rs mn)	Q1FY20	Q1FY19	YoY (%)	Q4FY19	QoQ (%)	Q1FY20E	Var (%)
Formulations	47,119	35,008	34.6	43,734	7.7	42,726	10.3
US	26,884	18,896	42.3	24,810	8.4	24,360	10.4
Europe	13,916	11,991	16.1	13,118	6.1	13,991	(0.5)
EM	3,134	2,565	22.2	2,891	8.4	2,616	19.8
ARV	3,185	1,556	104.7	2,915	9.3	1,758	81.1
APIs	7,322	7,480	(2.1)	9,167	(20.1)	7,653	(4.3)
Net Sales	54,445	42,503	28.1	52,921	2.9	50,379	8.1

Source: Company, BOBCAPS Research

Valuation methodology

We lower our target EV/EBITDA multiple for ARBP from 10x to 9x and prune FY20/FY21 EPS estimates by 2-3% to Rs 48/Rs 51 to account for potential disruption in US sales from (1) resolution delays at Units 1, 9 and 11, and (2) slower-than-expected Sandoz integration. On rolling valuations forward, we reset Sep '20 target price of Rs 700 (Rs 810 earlier). Our implied P/E works out to 13.5x (vs. 16x earlier).

We retain BUY on favourable risk-reward as the stock appears to be pricing in the worst of the facility risk and some part of Unit 3 escalation. As per management, the company has worked meticulously to resolve two of the critical observations for Unit 3. Overall, we expect US sales (ex-Sandoz) to log an ~8% CAGR for FY19-FY21, with combined sales of US\$ 2.2bn in FY21. We retain our ex-Sandoz EBITDA growth estimate of 6% CAGR for FY19-FY21.

FIG 3 – REVISED ESTIMATES

(Rs bn)	New		Old		Change (%)	
	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E
Sales	244	279	248	278	(1.3)	0.5
EBITDA	49	55	50	56	(0.7)	(1.3)
EBITDA margin (%)	20.2	19.8	20.1	20.2	12bps	(38bps)
EPS (Rs)	48	51	48.9	52.3	(1.9)	(2.6)

Source: Company, BOBCAPS Research

FIG 4 – RELATIVE STOCK PERFORMANCE



Source: NSE

Key risks

- US approval delays and Sandoz execution:** The US forms the single largest delta in our operating profit estimates for FY19-FY21 (80% of incremental profit); hence, delays in key approvals and execution hurdles in the Sandoz acquisition are key risk factors.

- **Regulatory risk:** ARBP supplies to the US from multiple plants. The key oral facilities are Unit 3 and Unit 7, and the key injectable plant is Unit 4. While the FDA inspection at Unit 4 was completed in Dec'18 (EIR received), the other units are due for inspection in the next six months. We note that ARBP has now started most of the oral filings from the new Unit 10. Escalation of OAI (official action indicated) observations on two units (API units 1 & 9) and the warning letter received for intermediate Unit 11 are key risks to estimates.

FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue	164,630	195,634	244,436	279,019	287,572
EBITDA	37,718	39,519	49,357	55,258	56,355
EBIT	32,138	32,839	39,153	42,275	42,392
Net interest income/(expenses)	(777)	(2,626)	(2,878)	(3,299)	(2,566)
Other income/(expenses)	1,020	1,157	1,174	777	560
Exceptional items	0	0	0	0	0
EBT	32,381	31,370	37,449	39,754	40,386
Income taxes	8,183	7,268	9,362	9,938	10,097
Extraordinary items	0	(483)	0	0	0
Min. int./Inc. from associates	(29)	(25)	0	0	0
Reported net profit	24,227	23,642	28,087	29,815	30,290
Adjustments	0	483	0	0	0
Adjusted net profit	24,227	24,126	28,087	29,815	30,290

Balance Sheet

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Accounts payables	26,274	26,771	40,181	45,866	47,272
Other current liabilities	15,324	24,390	21,999	25,112	25,881
Provisions	2,567	2,273	2,840	3,242	3,341
Debt funds	47,710	69,668	122,168	97,734	73,301
Other liabilities	0	0	0	0	0
Equity capital	586	586	586	586	586
Reserves & surplus	117,001	138,686	163,827	190,713	218,073
Shareholders' fund	117,587	139,272	164,413	191,299	218,659
Total liabilities and equities	209,462	262,373	351,601	363,253	368,454
Cash and cash eq.	12,616	19,594	13,941	8,263	7,737
Accounts receivables	38,788	47,771	66,969	76,444	78,787
Inventories	58,584	72,456	80,363	84,088	86,665
Other current assets	15,324	17,518	21,999	25,112	25,881
Investments	3,115	3,602	3,602	3,602	3,602
Net fixed assets	47,365	56,936	120,232	121,249	121,286
CWIP	15,829	16,685	16,685	16,685	16,685
Intangible assets	17,841	27,811	27,811	27,811	27,811
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	209,462	262,373	351,601	363,253	368,454

Source: Company, BOBCAPS Research

Cash Flows

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Net income + Depreciation	29,807	30,322	38,291	42,799	44,253
Interest expenses	777	2,626	2,878	3,299	2,566
Non-cash adjustments	0	0	0	0	0
Changes in working capital	(12,847)	(15,780)	(19,999)	(7,113)	(3,416)
Other operating cash flows	0	0	0	0	0
Cash flow from operations	17,737	17,168	21,169	38,984	43,403
Capital expenditures	(22,593)	(26,028)	(73,500)	(14,000)	(14,000)
Change in investments	(657)	(487)	0	0	0
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(23,250)	(26,515)	(73,500)	(14,000)	(14,000)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	14,069	21,958	52,500	(24,434)	(24,434)
Interest expenses	(777)	(2,626)	(2,878)	(3,299)	(2,566)
Dividends paid	(2,641)	(2,930)	(2,930)	(2,930)	(2,930)
Other financing cash flows	2,344	(77)	(16)	0	0
Cash flow from financing	12,995	16,325	46,677	(30,662)	(29,929)
Changes in cash and cash eq.	7,482	6,978	(5,654)	(5,678)	(526)
Closing cash and cash eq.	12,616	19,594	13,940	8,263	7,737

Per Share

Y/E 31 Mar (Rs)	FY18A	FY19A	FY20E	FY21E	FY22E
Reported EPS	41.3	40.4	47.9	50.9	51.7
Adjusted EPS	41.3	41.2	47.9	50.9	51.7
Dividend per share	2.5	2.5	2.5	2.5	2.5
Book value per share	200.9	238.0	281.0	326.9	373.6

Valuations Ratios

Y/E 31 Mar (x)	FY18A	FY19A	FY20E	FY21E	FY22E
EV/Sales	2.1	1.8	1.5	1.6	1.4
EV/EBITDA	9.4	9.1	7.6	7.8	7.4
Adjusted P/E	13.4	13.5	11.6	10.9	10.7
P/BV	2.8	2.3	2.0	1.7	1.5

DuPont Analysis

Y/E 31 Mar (%)	FY18A	FY19A	FY20E	FY21E	FY22E
Tax burden (Net profit/PBT)	74.8	76.9	75.0	75.0	75.0
Interest burden (PBT/EBIT)	100.8	95.5	95.6	94.0	95.3
EBIT margin (EBIT/Revenue)	19.5	16.8	16.0	15.2	14.7
Asset turnover (Revenue/Avg TA)	28.2	26.1	24.7	24.2	24.7
Leverage (Avg TA/Avg Equity)	1.4	1.5	1.6	1.6	1.4
Adjusted ROAE	23.1	18.8	18.5	16.8	14.8

Source: Company, BOBCAPS Research | Note: TA = Total Assets

Ratio Analysis

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
YoY growth (%)					
Revenue	10.4	18.8	24.9	14.1	3.1
EBITDA	9.8	4.8	24.9	12.0	2.0
Adjusted EPS	5.3	(0.4)	16.4	6.2	1.6
Profitability & Return ratios (%)					
EBITDA margin	22.9	20.2	20.2	19.8	19.6
EBIT margin	19.5	16.8	16.0	15.2	14.7
Adjusted profit margin	14.7	12.3	11.5	10.7	10.5
Adjusted ROAE	23.1	18.8	18.5	16.8	14.8
ROCE	22.8	18.2	16.3	15.0	14.8
Working capital days (days)					
Receivables	86	89	100	100	100
Inventory	130	135	120	110	110
Payables	58	50	60	60	60
Ratios (x)					
Gross asset turnover	2.1	1.9	1.4	1.4	1.4
Current ratio	2.8	2.9	2.8	2.6	2.6
Net interest coverage ratio	41.4	12.5	13.6	12.8	16.5
Adjusted debt/equity	0.3	0.4	0.7	0.5	0.3

Source: Company, BOBCAPS Research

Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

HISTORICAL RATINGS AND TARGET PRICE: AUROBINDO PHARMA (ARBP IN)



B – Buy, A – Add, R – Reduce, S – Sell

Rating distribution

As of 31 July 2019, out of 77 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 44 have BUY ratings, 16 are rated ADD, 8 are rated REDUCE and 9 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance, wealth management and portfolio management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.